This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Jevtana
  • /
  • PROSTAC: Multicentre Biomarker Study in CRPC Treat...
Clinical trial

PROSTAC: Multicentre Biomarker Study in CRPC Treated With Chemotherapy

Read time: 1 mins
Last updated:1st May 2014
Prospective Multi-centre Study of Prognostic Factors in Castration Resistant PROState Cancer Treated With doceTaxel and Cabazitaxel (PROSTAC).


Study Type: Observational
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Multi-centre Study of Prognostic Factors in Castration Resistant PROState Cancer Treated With doceTaxel or Cabazitaxel
Estimated Enrollment: 402
Study Start Date: May 2014
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)

Groups/Cohorts:
- Docetaxel
- Cabazitaxel
Category Value
Study start date 2014-05-01

View full details